Delfi Diagnostics

Notes

Delfi Diagnostics is a biotechnology company headquartered in Baltimore, Maryland, focused on developing blood-based tests for early cancer detection. The company was founded by leading researchers from Johns Hopkins University who pioneered the field of fragmentomics - the study of cell-free DNA fragmentation patterns.

Delfi's approach analyzes the patterns and characteristics of cell-free DNA fragments circulating in the blood, which differ between healthy individuals and those with cancer. This fragmentomics approach offers potential advantages in sensitivity and cost-effectiveness compared to other liquid biopsy methods.

The company's lead product, DELFI, is being developed for multi-cancer early detection, with a particular focus on lung cancer screening. Delfi has raised significant venture capital funding to advance its clinical development programs and commercialization efforts.

Team

• Victor Velculescu, M.D., Ph.D. - Co-founder & CEO
• Luis Diaz, Jr., M.D. - Co-founder & Board Member (Head of Division of Solid Tumor Oncology at Memorial Sloan Kettering)
• Robert B. Scharpf, Ph.D. - Co-founder & CSO
• Jillian Phallen, Ph.D. - Co-founder & VP of Product Development

Additional Research Findings

• Founded by Johns Hopkins University researchers
• Pioneered fragmentomics for cancer detection
• Lead product: DELFI multi-cancer early detection blood test
• Focus on lung cancer screening as initial application
• Based in Baltimore, Maryland
• Raised over $225 million in funding (Series A and Series B)
• Investors include Third Rock Ventures, Foresite Capital, and others
• Developing FirstLook Lung test for lung cancer screening
• Technology analyzes cell-free DNA fragmentation patterns

Sources

• Delfi Diagnostics Website
• Delfi Diagnostics LinkedIn
• Johns Hopkins Research Origins
• Crunchbase Profile